These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7198457)

  • 81. [Pharmacokinetic study of tiadenol in rats].
    Rousselet F; Clenet M; Gueris J
    Ann Pharm Fr; 1986; 44(6):431-6. PubMed ID: 3619321
    [No Abstract]   [Full Text] [Related]  

  • 82. "The influence of conformational factors on the metabolic conjugation of aryloxyacetates"--a comment.
    Kennard CH; Smith G
    J Pharm Pharmacol; 1988 May; 40(5):380. PubMed ID: 2899641
    [No Abstract]   [Full Text] [Related]  

  • 83. Glucuronic acid conjugates of clofibrate: four isomeric structures.
    Hignite CE; Tschanz C; Lemons S; Wiese H; Azarnoff DL; Huffman DH
    Life Sci; 1981 May; 28(18):2077-81. PubMed ID: 7242269
    [No Abstract]   [Full Text] [Related]  

  • 84. Stereoselective effects of chiral clofibric acid analogs on rat peroxisome proliferator-activated receptor alpha (rPPAR alpha) activation and peroxisomal fatty acid beta-oxidation.
    Rangwala SM; O'Brien ML; Tortorella V; Longo A; Loiodice F; Noonan DJ; Feller DR
    Chirality; 1997; 9(1):37-47. PubMed ID: 9094202
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Different behavior toward racemization in basic media from chiral analogs of clofibric acid, the active metabolite of the antilipidemic drug clofibrate.
    Ferorelli S; Loiodice F; Longo A; Molfetta A; Tortorella V; Amoroso R
    Chirality; 2000 Nov; 12(10):697-704. PubMed ID: 11054827
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Simultaneous GLC determination of clofibrate and clofibric acid in human plasma.
    Wolf MS; Zimmerman JJ
    J Pharm Sci; 1980 Jan; 69(1):92-3. PubMed ID: 7354454
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Characterization and formation of the glutathione conjugate of clofibric acid.
    Shore LJ; Fenselau C; King AR; Dickinson RG
    Drug Metab Dispos; 1995 Jan; 23(1):119-23. PubMed ID: 7720514
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Effect of rodent hepatocarcinogenic peroxisome proliferators on fatty acyl-CoA oxidase, DNA synthesis, and apoptosis in cultured human and rat hepatocytes.
    Perrone CE; Shao L; Williams GM
    Toxicol Appl Pharmacol; 1998 Jun; 150(2):277-86. PubMed ID: 9653058
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Clofibrate treatment promotes branched-chain amino acid catabolism and decreases the phosphorylation state of mTOR, eIF4E-BP1, and S6K1 in rat liver.
    Ishiguro H; Katano Y; Nakano I; Ishigami M; Hayashi K; Honda T; Goto H; Bajotto G; Maeda K; Shimomura Y
    Life Sci; 2006 Jul; 79(8):737-43. PubMed ID: 16616211
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [Treatment of coronary heart disease with diet and lipid-reducing agents].
    Sailer D; Kolb S
    Fortschr Med; 1982 Nov; 100(43):2005-10. PubMed ID: 7152437
    [No Abstract]   [Full Text] [Related]  

  • 91. Probing the fibrate binding specificity of rat liver fatty acid binding protein.
    Chuang S; Velkov T; Horne J; Wielens J; Chalmers DK; Porter CJ; Scanlon MJ
    J Med Chem; 2009 Sep; 52(17):5344-55. PubMed ID: 19663428
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Enantiomers of clofibric acid analogs have opposite actions on rat skeletal muscle chloride channels.
    Conte-Camerino D; Mambrini M; DeLuca A; Tricarico D; Bryant SH; Tortorella V; Bettoni G
    Pflugers Arch; 1988 Nov; 413(1):105-7. PubMed ID: 2464159
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Separation and measurement of clofibroyl coenzyme A and clofibric acid in rat liver after clofibrate adminstration by reversed-phase high-performance liquid chromatography with photodiode array detection.
    Lygre T; Aarsaether N; Stensland E; Aarsland A; Berge RK
    J Chromatogr; 1986 Aug; 381(1):95-105. PubMed ID: 3771728
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Pharmacokinetics and distribution of a fluoresceinated glycosaminoglycan, sulodexide, in rats. Part I: Pharmacokinetics in rats.
    Cristofori M; Mastacchi R; Barbanti M; Sarret M
    Arzneimittelforschung; 1985; 35(10):1513-6. PubMed ID: 4074405
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Short-term tests with a pilot sewage plant and biofilm reactors for the biological degradation of the pharmaceutical compounds clofibric acid, ibuprofen, and diclofenac.
    Zwiener C; Frimmel FH
    Sci Total Environ; 2003 Jun; 309(1-3):201-11. PubMed ID: 12798104
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Difference between guinea pig and rat in the liver peroxisomal response to equivalent plasmatic level of ciprofibrate.
    Pacot C; Petit M; Rollin M; Behechti N; Moisant M; Deslex P; Althoff J; Lhuguenot JC; Latruffe N
    Arch Biochem Biophys; 1996 Mar; 327(1):181-8. PubMed ID: 8615689
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Route-dependent comparative metabolism of [14C]toluene 2,4-diisocyanate and [14C]toluene 2,4-diamine in Fischer 344 rats.
    Timchalk C; Smith FA; Bartels MJ
    Toxicol Appl Pharmacol; 1994 Feb; 124(2):181-90. PubMed ID: 8122263
    [TBL] [Abstract][Full Text] [Related]  

  • 98. [Toxicological and pharmacological studies on a new drug: pirfibrate (EL-466) (author's transl)].
    de la Fuente R; Santos M
    Arch Farmacol Toxicol; 1980 Dec; 6(3):255-64. PubMed ID: 7305456
    [No Abstract]   [Full Text] [Related]  

  • 99. Xanthone analogues of clofibrate / Synthesis and biological evaluation as antagonists of lipolysis in vitro.
    Gaion RM; Valenti P; Montanari P; Da Re P
    Arzneimittelforschung; 1982; 32(5):499-502. PubMed ID: 7201826
    [TBL] [Abstract][Full Text] [Related]  

  • 100. [Pharmacologic therapy of arteriosclerosis: current possibilities].
    Priego JG; Díaz Méndez M
    Med Clin (Barc); 1984 Oct; 83(10):431-2. PubMed ID: 6503408
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.